Personalis (NASDAQ:PSNL) Shares Up 6.8% – What’s Next?

Personalis, Inc. (NASDAQ:PSNL) shares rose 6.8% during trading on Wednesday . The stock traded as high as $8.16 and last traded at $8.1350. 87,377 shares traded hands during trading, a decline of 92% from the average session volume of 1,103,720 shares. The stock had previously closed at $7.62.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Guggenheim boosted their price target on Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. BTIG Research raised their price objective on Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital restated a “buy” rating and issued a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.29.

Personalis Trading Up 17.5%

The stock has a market cap of $864.06 million, a price-to-earnings ratio of -11.06 and a beta of 1.92. The stock has a fifty day simple moving average of $7.83 and a 200-day simple moving average of $6.31.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in shares of Personalis in the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. acquired a new position in shares of Personalis in the second quarter valued at $34,000. BNP Paribas Financial Markets lifted its position in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the period. Alpha Wealth Funds LLC acquired a new stake in Personalis during the second quarter worth $66,000. Finally, Farther Finance Advisors LLC bought a new stake in Personalis in the 3rd quarter valued at $66,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.